Close Menu

ER/PgR

A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and were associated with lower response to aromatase inhibitors. 

The two companies will evaluate the efficacy of the combination in patients with ER-positive, HER2-negative, advanced breast cancer.

At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.

The authors of a recently published study suggested that testing metastatic breast cancer patients for kinase fusions may open up additional treatment opportunities.

Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.